Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Lyxumia added to Lantus meets Phase III trial endpoint

This article was originally published in Scrip

Executive Summary

The life cycle management of the Sanofi blockbuster diabetes drug Lantus has become clearer after the French multinational pharma revealed that its investigational, once-daily GLP-1 agonist, Lyxumia (lixisenatide) met its primary endpoint when added to the company’s top-selling product Lantus (insulin glargine) and metformin as a treatment of type 2 diabetes. Sanofi has reported that the combination achieved the primary efficacy endpoint of significantly reducing HbA1c from baseline to week 24 versus placebo in a Phase III trial dubbed GetGoal Duo 1. In the trial, HbA1c <7%>

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC015468

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel